Business
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
SAN ANTONIO, May 08, 2026--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026.
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/23ffb3b390f5e7ae95296f053ac44e01"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y2BP0SEuc5aZuGNLbI9ieg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMg--/https://media.zenfs.com/en/business-wire.com/23ffb3b390f5e7ae95296f053ac44e01","width":480,"height":201},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/jt.9Wy6U.xHSPBWPnpjBkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI2OA--/https://media.zenfs.com/en/business-wire.com/23ffb3b390f5e7ae95296f053ac44e01","width":480,"height":201}},"lazy":false},{"type":"text","content":"CyPath® Lung cancer diagnostic unit sales rise 146% year-over-year","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath® Lung benefits","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"SAN ANTONIO, May 08, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026.","length":320,"tagName":"p"},{"type":"text","content":"Q1 2026 Highlights","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CyPath® Lung unit sales increased 146% year-over-year in the first quarter of 2026, reflecting accelerating physician adoption and expanding clinical use of the Company’s noninvasive lung cancer diagnostic.","length":206,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CyPath® Lung testing revenue increased approximately 114% to $361,000, compared to $169,000 in the first quarter of 2025.","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Total consolidated revenue decreased approximately 27% to $1.4 million, compared to $1.9 million for the first quarter of 2025, resulting from the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin services, including CyPath® Lung testing.","length":287,"tagName":"p","attribs":{}}]},{"val":...